Navigation Links
Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer
Date:8/28/2012

BATON ROUGE, La., Aug. 28, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that over‐express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over‐expressed in a wide range of cancers including ovarian cancer. In June, the Company presented results from the successful completion of a Phase 1 study of EP‑100 in advanced solid tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting.

"We are pleased with the continued momentum behind EP‑100 and the progress of enrollment as we begin the randomized treatment phase," said Dr. Hector Alila, CEO of Esperance. "We are encouraged with early results, and look forward to accelerating enrollment in a very important, underserved patient population and providing an update on the clinical progress over time."

The randomized, Phase 2 trial of EP‑100 in combination with paclitaxel versus paclitaxel alone in patients with histologically confirmed epithelial ovarian carcinomas expressing LHRH‐receptors is actively enrolling patients in key clinical sites across the United States. Rationale for the study is based on the positive clinical evidence from escalating doses in 38 patients in the Phase 1 study and on preclinical studies showing synergies between EP‑100 and various chemotherapeutic agents.

About EP‑100

EP‑100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP™) platform technology, is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their s
'/>"/>

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
2. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
3. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
4. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
5. Actinium Pharmaceuticals Strengthens Management Team
6. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
7. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
8. Access Pharmaceuticals To Host Second Quarter Investor Call on Thursday, August 23, 2012
9. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
10. Nouveau Life Pharmaceuticals (NOUV) Releases Calcium & Vitamin D for Strong Bones
11. Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... OAKS, Calif., April 13, 2011 Amgen (NASDAQ: ... first quarter financial results on Wednesday, April 20, 2011 after ... be followed by a conference call with the investment community ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
... 13, 2011 Perrigo (Nasdaq: PRGO;TASE) today announced that ... TEVA ), has received final OTC approval to sell ... tablets; the generic equivalents of Sanofi-Aventis, Allegra 60 mg ... for these products, and Teva and Sanofi-Aventis have settled ...
Cached Medicine Technology:Amgen Announces Webcast of 2011 First Quarter Financial Results 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 3
(Date:7/9/2014)... has risen dramatically in Western societies. One frequently cited ... and have fewer infections than previous generations, thereby delaying ... researchers at Sahlgrenska Academy, University of Gothenburg, monitored children ... the immune system in relation to allergic disease. All ... Vstra Gtaland Region, half of them on farms that ...
(Date:7/8/2014)... Restoration has been awarded up to $15 million by ... four -year project aiming to help brain-injured people restore ... neurosurgery, engineering, neurobiology, psychology and physics will collaborate to ... the brain. , Memory is the process in which ... store it and retrieve it. Certain types of illnesses ...
(Date:7/8/2014)... hygiene rates were found to be three times higher ... there were no auditors present, according to a study ... The study, titled, "Quantification of the Hawthorne effect in ... a retrospective cohort study," published today on-line in the ... author Dr. Jocelyn Srigley, who did the study as ...
(Date:7/8/2014)... have increased risks of dying at a young age ... stroke, diabetes, and kidney and liver diseases, according to ... large studies of people from three countries. The study, ... part of the National Institutes of Health, found that ... dramatic reduction in life expectancy compared with people of ...
(Date:7/8/2014)... Military physicians will soon pick up joysticks instead of ... with serious health threats. , James Gerard, M.D., a professor ... grant from the Department of Defense Office of Naval ... a video game that will train physicians on pediatric emergency ... use one of the most popular tools gaming ...
Breaking Medicine News(10 mins):Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:NCI study finds extreme obesity may shorten life expectancy up to 14 years 2Health News:Save, don't kill: SLU pediatrician to develop educational video game for training military physician 2
... Announce the Houston Tackles Autism Campaign, HOUSTON, ... running back Ahman Green, representatives from Reliant Energy, ... are holding a,news conference to raise awareness about ... book Playing Together: Tips from the Pros. ...
... Also Renews Commitment to Darfur, STAMFORD, Conn., Oct. ... more than $7,billion in aid to people in need ... AmeriCares President and CEO Curt Welling announced the milestone ... held at Westchester County Airport on Saturday., "I ...
... with their doctors , , MONDAY, Oct. 15 (HealthDay News) ... implantable defibrillators -- voluntarily stopped distribution of Sprint Fidelis ... wires could fracture, potentially triggering cardiac events. , The ... implanted defibrillators wondering what to do next. , But ...
... 15 Today, Easter Seals awarded members,of state ... Easter Seals annual convention currently being held in ... to honor public,officials -- elected and appointed -- ... for people with disabilities, and for all. ...
... ,Family,Matters, Study, BOSTON, Oct. 15 It could be ... look as if they,re,turning away from their family in favor ... A lot., A study led by Simmons School of ... importance to adolescents that they feel,valued by their family, and ...
... Calif., Oct. 15 Digirad Corporation,(Nasdaq: DRAD ... systems,and services to physicians, offices, hospitals and imaging ... Deloitte,s Technology Fast 50 Program,for San Diego. The ... and life sciences companies in the,San Diego area ...
Cached Medicine News:Health News:Reliant Energy, Houston Texans' Ahman Green and Matt Schaub Team to Hold News Conference, Book Signing to Raise Awareness about Autism 2Health News:Reliant Energy, Houston Texans' Ahman Green and Matt Schaub Team to Hold News Conference, Book Signing to Raise Awareness about Autism 3Health News:AmeriCares Passes $7 Billion Mark in Aid Distributed 2Health News:Defib Wire Warning Shouldn't Worry Most Users: Experts 2Health News:Defib Wire Warning Shouldn't Worry Most Users: Experts 3Health News:Defib Wire Warning Shouldn't Worry Most Users: Experts 4Health News:Easter Seals Awards State and Municipal Public Officials With 2007 Outstanding Advocate Awards 2Health News:A Best-Kept Secret of Your Teen: They Really Do Care What You Think, Simmons College Study Shows 2Health News:Digirad Corporation Named to Deloitte Technology Fast 50 2Health News:Digirad Corporation Named to Deloitte Technology Fast 50 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: